Tirzepatide

Tirzepatide

🔹 What is Tirzepatide? Class: Dual GLP-1 and GIP receptor agonist Mechanism:

• GLP-1 receptor activation: Enhances insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces food intake.
• GIP receptor activation: Stimulates insulin secretion and promotes fat storage.

By activating these two receptors, tirzepatide aims to improve glycemic control, reduce body weight, and enhance metabolic health. Primary Focus:

• Type 2 diabetes: Improves glycemic control.
• Obesity management: Significant weight loss observed in clinical trials.
• Metabolic health: Enhanced insulin sensitivity and reduced liver fat.

---

🔹 Oral Dosage

• Not applicable: Tirzepatide is administered via subcutaneous injection due to its peptide structure and poor oral bioavailability.

---

🔹 Injectable / Subcutaneous Dosage

• Dosing:
  • 2.5 mg subcutaneously once weekly for 4 weeks.
  • Increase to 5 mg subcutaneously once weekly for at least 4 weeks.
  • Further increase by 2.5 mg every 4 weeks as needed, up to a maximum of 15 mg per week.
• Frequency: Once weekly.
• Rationale: Weekly dosing aligns with the pharmacokinetics of tirzepatide, providing sustained receptor engagement.

Compounded formulation notes: Some clinics compound Tirzepatide with BPC-157 and Vitamin B6, or alternatively with Vitamin B12, administered based on the patient’s history, labs, and body composition.

---

🔹 Cycle Length

• Duration:
  • Obesity management: Clinical trials have typically lasted 72 weeks.
  • Type 2 diabetes: Duration varies; consult specific clinical guidelines.
• Evaluation: Ongoing studies are assessing long-term efficacy and safety.

---

🔹 Optimal Dosing Window

• Timing: Administered at any time of day, with or without food.
• Consistency: Administer on the same day each week to maintain steady drug levels.

---

✅ Educational Integration Example

• Protocol: 10 mg subcutaneously once weekly for 72 weeks.
• Paired with: Lifestyle modifications including dietary changes and physical activity.
• Rationale: Combines pharmacological intervention with behavioral changes to optimize weight loss and metabolic health.

---

🔹 Stacking Strategy (Educational / Complementary) Since tirzepatide targets multiple metabolic pathways, stacking strategies focus on enhancing mitochondrial function, fat metabolism, and muscle preservation: 🔸 Mitochondrial & Energy Support

• CoQ10: Supports the electron transport chain and ATP synthesis.
• PQQ: Promotes mitochondrial biogenesis and function.
• L-Carnitine: Facilitates fatty acid transport into mitochondria for energy production.

🔸 Fat Metabolism & Insulin Sensitivity

• Berberine: Improves insulin sensitivity and supports lipid metabolism.
• Omega-3 fatty acids: Reduce inflammation and support metabolic health.

🔸 Muscle Preservation

• BCAAs: Support muscle protein synthesis and prevent muscle loss during weight loss.
• Creatine: Enhances muscle strength and preserves lean mass.

Rationale: Combining tirzepatide with complementary agents can enhance weight loss, improve metabolic health, and preserve muscle mass.

---

🔹 Clinical Pearl

• Some clinicians report Tirzepatide outperforming Semaglutide for weight loss specifically, likely due to its dual-receptor (GLP-1 + GIP) mechanism.

---

⚠️ Safety Notes

• Gastrointestinal side effects: Nausea, diarrhea, and vomiting are common, especially during dose escalation.
• Hypoglycemia: Monitor blood glucose levels, particularly in individuals with diabetes.
• Contraindications: Not recommended for individuals with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
• Pancreatic enzyme monitoring: Same contraindication and pancreatic-enzyme monitoring considerations apply here as with Semaglutide, given the shared GLP-1/GIP class effects — see the Semaglutide entry for the fuller monitoring protocol.
• Gallbladder disease: Reported in about 0.6% of users in one study.
• Drug interactions: GLP-1/GIP drugs delay gastric emptying, which can affect the absorption of other medications.
• Availability: Approved for use in several countries, including the United States and European Union.

Adjunct protocol for pre-existing GI conditions: For patients with a pre-existing history of GERD or Barrett’s Esophagus who are also on Tirzepatide, some clinicians use an adjunct protocol — this is not a general recommendation, only for patients with these specific histories:

• Hx of GERD: Alka Seltzer Gold, AM/PM.
• Hx of Barrett’s Esophagus: Alka Seltzer Gold plus oral BPC-157, reported as protective — heals ulcers and helps prevent new damage.

Disclaimer: Do not rely on any dosing information provided, this is for educational and research only. Always double and triple check alternative references for education. Please consult with healthcare provider for your specific dosing and protocol if applicable.